疏血通注射液联合桂哌齐特治疗短暂性脑缺血发作的疗效观察

目的探讨疏血通注射液联合桂哌齐特治疗短暂性脑缺血发作的临床疗效。方法选取2014年1月—2016年1月延安市人民医院收治的短暂性脑缺血发作患者132例,随机分为对照组和治疗组,每组各66例。对照组静脉滴注马来酸桂哌齐特注射液,320 mg加入生理盐水500 m L,1次/d;治疗组在对照组的基础上静脉滴注疏血通注射液,6 m L加入生理盐水250 m L,1次/d。两组均连续治疗14 d。观察两组患者的临床疗效,同时比较两组治疗前后血浆黏滞度(CP)、血细胞比容(HCT)、纤维蛋白原(FIB)、血小板聚集率(PAR)和ABCD评分的变化情况。结果治疗后,对照组和治疗组的总有效率分别为83.33%、93.94%,两组比较差异具有统计学意义(P0.05)。治疗后,两组CP、HCT、FIB和PAR显著降低,同组治疗前后差异具有统计学意义(P0.05);且治疗组这些观察指标降低程度比对照组更明显,两组比较差异有统计学意义(P0.05)。治疗后,治疗组ABCD评分显著低于对照组,且其改善值优于对照组,两组ABCD评分变化比较差异具有统计学意义(P0.05)。结论疏血通注射液联合桂哌齐特治疗短暂性脑缺血发作具有较好的临床疗效,可有效改善患者血液流变学相关指标,降低早期发生脑梗死的风险,具有一定的临床推广应用价值。

Clinical observation of Shuxuetong Injection combined with cinepazide in treatment of transient ischemic attack

Objective To investigate the clinical effect of Shuxuetong Injection combined with cinepazide in treatment of transient ischemic attack. Methods Patients (132 cases) with transient ischemic attack in Yan''an People''s Hospital from January 2014 to January 2016 were randomly divided into control and treatment groups, and each group had 66 cases. The patients in the control group were iv administered with Cinepazide Maleate Injection, 320 mg added into normal saline 500 mL, once daily. The patients in the treatment group were iv administered with Shuxuetong Injection on the basis of the control group, 6 mL added into normal saline 250 mL, once daily. The patients in two groups were treated for 14 d. After treatment, the efficacy was evaluated, and CP, HCT, FIB, PAR, and ABCD scores in two groups before and after treatment were compared. Results After treatment, the efficacies in the control and treatment groups were 83.33% and 93.94%, respectively, and there were differences between two groups (P<0.05). After treatment, the indexes of CP, HCT, FIB, and PAR in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the decrease degree of these observational indexes in the treatment group was more significant than that in the control group, with significant difference between two groups (P<0.05). After treatment, ABCD scores and it''s improvement in the treatment group were obviously better than those in the control group, and there were differences between two groups (P<0.05). Conclusion Shuxuetong Injection combined with cinepazide has a good clinical efficacy in treatment of transient ischemic attack, which can effectively improve blood rheology indexes and reduce the risk of early cerebral infarction, which has a certain clinical application value.